Relay Therapeutics, Inc.
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Source
97 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027
1415 Louisiana St., Suite 3325, Houston, TX 77002
Gross Bookings grew 20% year-over-year on a constant currency basis
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an…
FISCAL 2027 FIRST QUARTER RESULTS
New Independent Directors bring deep consumer, financial and operational expertise – strengthening the Board as Kraft Heinz advances its…
Third Quarter Highlights and Recent Developments
- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -
Solstice Advanced Materials Reports Third Quarter 2026 Results